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1  | INTRODUC TION
Colorectal cancer (CRC) is the third most common cause of cancer-re-
lated death worldwide.1 Systemic chemotherapy plays a pivotal role in 
treating CRC, and oxaliplatin (L-OHP), a third-generation diaminocyclo-
hexane platinum compound, has been widely used as a key drug for both 
resectable and unresectable CRC.2-4 Clinical data suggest that KRAS 
mutation, which occurs in approximately 40-45% of CRC,5,6 hampers 
the effects of L-OHP. The survival benefit of CRC patients who received 
L-OHP-based chemotherapy as an adjuvant therapy was significantly 
poorer in the KRAS mutant group compared to the KRAS wild group.7,8 
The mechanisms of L-OHP resistance are complex and could be affected 
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Abstract
The NF-kappa B (NF-κB) pathway plays a pivotal role in tumor progression and chem-
oresistance, and its inhibition has been shown to suppress tumor growth in a variety 
of preclinical models. Recently, we succeeded in synthesizing a water-soluble inject-
able type of curcumin β-D-glucuronide (CMG), which is converted into a free-form of 
curcumin by β-glucuronidase in vivo. Herein, we aimed to clarify the efficacy, safety 
and pharmacokinetics of CMG in a xenograft mouse model. First, we confirmed that 
the presence of KRAS/TP53 mutations significantly increased the IC50 of oxaliplatin 
(L-OHP) and NF-κB activity in HCT116 cells in vitro. Then, we tested the efficacy of 
CMG in an HCT116 colon cancer xenograft mice model. CMG demonstrated superior 
anticancer effects compared to L-OHP in an L-OHP-resistant xenograft model. With 
regard to safety, significant bodyweight loss, severe myelosuppression and AST/ALT 
elevation were observed in L-OHP-treated mice, whereas none of these toxicity was 
noted in CMG-treated mice. The combination of CMG and L-OHP exhibited addi-
tive effects in these xenograft models without increasing toxicity. Pharmacokinetic 
analysis revealed that high levels of free-form curcumin were maintained in the tumor 
tissue after 48 hours following CMG administration, but it was not detected in other 
major organs, such as the heart, liver and spleen. Immunohistochemistry revealed 
reduced NF-κB activity in the tumor tissue extracted from CMG-treated mice com-
pared with that from control mice. These results indicated that CMG could be a 
promising anticancer prodrug for treating colon cancer with minimal toxicity.
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by a variety of factors.9 However, NF-κB activation appears to play a 
pivotal role in L-OHP resistance. Porras et al demonstrated that NF-κB is 
activated in L-OHP-resistant colon cancer cell lines, and inhibition of the 
NF-κB pathway using curcumin, a natural polyphenol molecule derived 
from turmeric (Curcumin longa), recovers L-OHP-sensitivity.10
NF-κB inhibition is one of the major pharmacologic properties of 
curcumin and has been demonstrated in a number of preclinical mod-
els.11-14 For these reasons, curcumin could be a promising anticancer 
drug targeting the NF-κB pathway and enhancing L-OHP sensitivity. 
However, because curcumin is highly lipophilic,15 its bioavailability is 
very poor, and this has been the major obstacle for its clinical ap-
plication. Several researchers, including us, have tested the efficacy 
of orally administered curcumin in clinical trials and demonstrated 
several clinical benefits.16-20 However, the reported curcumin blood 
levels after oral administration have been too low to derive the maxi-
mum anti–tumor effects of curcumin.16-20 To overcome this problem, 
we recently succeeded in synthesizing a water-soluble injectable type 
of curcumin β-D-glucuronide (curcumin monoglucuronide, CMG), 
which was the major metabolite after oral intake of curcumin. We also 
verified that intravenously administered synthetic CMG is converted 
into a free-form of curcumin by β-glucuronidase (Figure 1) and can 
achieve more than 1000 times higher plasma curcumin levels com-
pared to orally administered conventional curcumin.21
In this study, we aimed to clarify the efficacy, safety and pharma-
cokinetics of CMG in a xenograft model using HCT116 cell lines with 
different mutation profiles of KRAS and TP53 genes.
2  | MATERIAL S AND METHODS
2.1 | Chemicals
Oxaliplatin and curcumin were purchased from FUJIFILM Wako Pure 
Chemical. Three known NF-κB inhibitors (Bay11-7082; IκBα kinase 
inhibitor, TPCA1; IκB kinase inhibitor, MG132; proteasome inhibitor) 
were purchased from Abcam for Bay11-7082 and TPCA1, or from 
Cayman Chemical for MG132, respectively. CMG was synthesized 
using a previous method (KNC Laboratories).21
2.2 | Cell culture
Three types of HCT116 colon cancer cell lines (KRAS mutant/
TP53 wild parental cell line, KRASm/TP53w; KRAS mutant/TP53 
homozygous knockout, KRASm/TP53-; and KRAS mutant heterozy-
gous knockout/TP53 wild, KRASw/TP53w) were purchased from 
the ATCC. RPMI1640 medium, FBS and penicillin/streptomycin so-
lution were purchased from Sigma Aldrich. HCT116 cells were cul-
tured once every 3 days in RPMI1640 medium with 10% FBS and 1% 
penicillin/streptomycin solution at 37°C in a 5% CO2 atmosphere.
2.3 | MTS assay
HCT116 cells were plated in 48-well plates at 4 × 105 cells per well. After 
24 hours, the cells were treated with L-OHP (0, 0.5, 1, 2, 4 and 10 μM in 
DMSO) or curcumin (0, 5, 10, 15, 20 and 25 μM in DMSO). Bay11-7082 
(0 and 5 μM in DMSO), TPCA1 (0 and 20 μM in DMSO) or MG132 (0 and 
0.5 μM in DMSO) were also tested with L-OHP (0 and 4 μM in DMSO) on 
KRASm/TP53- HCT116 cells. After 72 hours, cell viability was analyzed 
with the 3-(4,5-dimethylthiazol-2-yl)-5-(3- carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt) (MTS) assay using CellTiter 
96 AQueous One Solution Cell Proliferation Assay (Promega).
2.4 | NF-κB activity assay
HCT116 cells were plated in 48-well plates at 5 × 104 cells per well. After 
1 day, the cells were cultured in RPMI1640 medium (1% FBS) for 24 hours. 
They were transfected with pGL4.32 luc2P/NF-κB-RE plasmid (Promega) 
and pSF-PromMCS-βGal containing CMV promoter (Boca Scientific). At 
3 hours following gene transfection, the transfected cells were treated 
with various concentrations of curcumin in RPMI1640 medium (1% FBS) 
for 3 hours and then NF-κB activity was measured using a PicaGene 
Luminescence Kit (Toyo Ink); β-galactosidase activity was measured 
using a β-Galactosidase Assay Kit (OZ Biosciences). Gene transfection 
into cells was performed using Lipofectamine 2000 Transfection Reagent 
(Invitrogen). The cell lysates were prepared with Reporter Lysis 5 × Buffer 
(Promega). NF-κB activity was shown as luciferase/β-galactosidase.
2.5 | Assessment of efficacy and safety of curcumin 
β-D-glucuronide against KRASm/TP53w HCT116 
xenograft mice model
All animal experiments were approved by the Jikei University 
Institutional Animal Care and Use Committee (Permission No. 2018-
004) and Nissei Bilis (Permission No. 1804-13).
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In BALB/c/AnNCr j-nu/nude mice (7-8 female mice per group, 
6 weeks old, Charles River Laboratories Japan), 4 × 106 KRASm/
TP53w HCT116 cells were subcutaneously transplanted. After 
9 days following transplantation, they were grouped by stratified 
randomization with tumor volume (day 0). Saline (10 mL/kg) as a 
control, 90 mg/kg of CMG (equivalent to 61 mg/kg of curcumin) 
i.p. or i.v. and 500 mg/kg of synthetic curcumin orally were ad-
ministered thrice a week for 3 weeks (days 0, 3, 5, 7, 10, 12, 14, 
17 and 19). L-OHP was administered at a dose of 8 mg/kg i.p. 
twice a week for 3 weeks (days 0, 3, 7, 10, 14 and 17). A com-
bination of 8 mg/kg of L-OHP (twice a week for 3 weeks) with 
90 mg/kg of CMG (thrice a week for 3 weeks) was also tested. 
Tumor volume was assessed seven times, on days 0, 3, 7, 10, 14, 
17 and 21, with the length, height and width of the tumor being 
measured using a pair of calipers. Tumor volume was calculated as 
length × width2 × 0.5 (mm3). Body weight was measured on days 
0, 7, 14 and 21 using electronic scales (UW4200S, Shimadzu). 
Blood samples were collected and submitted for hematological 
and biochemical testing on day 21. Tumor tissue, the heart, the 
liver and the spleen were extracted from the mice after complete 
blood removal on day 21.
2.6 | Assessment of efficacy and safety of curcumin 
β-D-glucuronide in KRASm/TP53- HCT116 xenograft 
mice model
In BALB/cSlc-nu/nu mice (7 female mice per group, 6 weeks old, Japan 
SLC), 4 × 106 KRASm/TP53- HCT116 cells were subcutaneously trans-
planted. After 7 days following transplantation, with saline (10 mL/kg) 
as a control, 90 mg/kg of CMG were administered i.p. thrice a week for 
3 weeks (days 0, 3, 5, 7, 10, 12, 14, 17 and 19). Eight mg/kg of L-OHP 
alone or 8 mg/kg of L-OHP (twice a week for 3 weeks) in combination 
with 90 mg/kg of CMG (thrice a week for 3 weeks) were administered 
i.p. twice a week for 3 weeks (days 0, 3, 7, 10, 14 and 17). Tumor volume 
and body weight were assessed as described above.
2.7 | Pharmacokinetic analysis
Free-form curcumin levels in serum, tumor tissue, heart, liver and spleen 
obtained from 90 mg/kg of CMG i.v.-administered groups in the KRASm/
TP53w HCT116 xenograft mice model on day 21 were measured.
2.8 | Immunohistochemistry
The tumor tissues were extracted from the KRASm/TP53- HCT116 
xenograft mice model on day 21. The samples were then fixed with 
formalin and embedded in paraffin. After heat-induced antigen-
retrieval at 95℃ for 20 minutes, serial sections were incubated 
overnight at 4℃ with rabbit monoclonal anti–human p65 antibody 
(1:300 dilution; Abcam) or rabbit monoclonal anti–human Ikappa-B 
(IκB) antibody (1:50 dilution; Cell Signaling Technology). Images were 
captured with NanoZoomer Digital Pathology 2 (Hamamatsu). A 
quantitative analysis of staining signals from 3 different images was 
performed using ImageJ software.22
2.9 | Statistical analysis
Data are shown as the mean ± standard deviation (SD). Significant 
difference was analyzed using Student's t test. P-values < 0.05 were 
considered statistically significant.
3  | RESULTS
3.1 | KRAS mutation/TP53 loss attenuates 
sensitivity to L-OHP
First, we tested whether KRAS/TP53 mutation status could affect 
sensitivity to L-OHP using three HCT116 cell lines with/without 
KRAS/TP53 mutation. IC50 values of L-OHP were 1.0/1.7/4.8 μM for 
KRASw/TP53w, KRASm/TP53w and KRASm/TP53- HCT116 cells, 
respectively (Figure 2A). In contrast, the IC50 values of curcumin 
were 19.6/20.0/17.4 μM for KRASw/TP53w, KRASm/TP53w and 
KRASm/TP53- HCT116 cells, respectively (Figure 2B). Thus, KRAS 
mutation or TP53 loss in HCT116 cells significantly increased the 
IC50 of L-OHP but did not attenuate the anti–tumor effects of cur-
cumin in vitro.
3.2 | KRAS mutation/TP53 loss increases NF-κB 
activity 
NF-κB activity in the three HCT116 cell lines mentioned above was 
measured using luciferase assay. As shown in Figure 3A, NF-κB activ-
ity was highest in KRASm/TP53- cells, followed by KRASm/TP53w 
and KRASw/TTP53w cells. As expected, curcumin suppressed 
NF-κB activity in a dose-dependent manner in KRASm/TP53- and 
KRASm/TP53w cells (Figure 3B,C).
3.3 | Curcumin β-D-glucuronide and L-OHP exhibit 
potent anti–tumor effects on KRASm/TP53w 
HCT116 xenograft model
First, we confirmed that there was no significant difference in the 
free-form curcumin levels in the tumor tissue between the CMG 
i.v. and i.p. groups (Figure S1). Based on these data, the i.p. route 
was selected for our following in vivo experiments. As shown in 
Figure 4, the mean tumor volume of the control group increased 
over time from 28.6 ± 10.3 mm3 on day 0 to 344.0 ± 250.2 mm3 
on day 21. The mean tumor volume of each treatment group on 
day 21 was 310.5 ± 221.6 mm3 in the conventional curcumin group, 
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213.4 ± 67.8 mm3 in the CMG group, 153.7 ± 112.7 mm3 in the 
L-OHP group, and 107.8 ± 79.7 mm3 in the L-OHP and CMG com-
bination groups. Thus, both CMG and L-OHP suppressed tumor 
growth by 38% and 55%, respectively, compared to the control 
group (Figure 4A). The combination of L-OHP and CMG showed 
higher anti–tumor effects compared to CMG or L-OHP monother-
apy, and significantly suppressed tumor growth by 69% compared 
to the control group (P < 0.05).
3.4 | Curcumin β-D-glucuronide exhibits superior 
anti–tumor effects on L-OHP resistant KRASm/TP53- 
HCT116 xenograft model compared to L-OHP
Next, we tested the efficacy of CMG using the xenograft model derived 
from KRASm/TP53- HCT116 cells, which demonstrated the highest 
NF-κB activity and resistance to L-OHP in vitro. As shown in Figure 4B, 
the mean tumor volume of the control group increased over time from 
F I G U R E  2   Anticancer effects of (A) L-OHP and (B) curcumin on each HCT116 cell line in vitro. The IC50 values of L-OHP and curcumin on 
each HCT116 cell line (KRASw/TP53w, KRASm/TP53w and KRASm/TP53-) at 72 hours post−treatment. Data represent means ± SD (n = 3). 
*P < 0.01, as compared to KRASw/TP53w HCT116; #P < 0.01, as compared to KRASm/TP53w HCT116; **P < 0.01, as compared to KRASw/
TP53w HCT116 and KRAS m/TP53w HCT116
F I G U R E  3   Inhibition of NF-κB activity by curcumin in vitro. A, Baseline NF-κB activity on each HCT116 cell line. *P < 0.05 and **P < 0.01, 
as compared to KRASw/TP53w cells; #P < 0.01, as compared to KRASm/TP53w. B, Dose-dependent inhibition of NF-κB activity by 
curcumin in KRASm/TP53w cells. The IC50 value of curcumin is 20.0 μM. ##P < 0.01, as compared to no treatment. C, Dose-dependent 
inhibition of NF-κB activity by curcumin in KRASm/TP53- cells. IC50 value of curcumin is 17.4 μM. ###P < 0.05, as compared to no treatment
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74.7 ± 38.8 mm3 on day 0 to 825.3 ± 404.1 mm3 on day 21. The mean 
tumor volume of each treatment group on day 21 was 708.0 ± 291.7 mm3 
in the L-OHP group, 420.7 ± 175.5 mm3 in the CMG group, and 
353.0 ± 225.1 mm3 in the L-OHP and CMG combination group. Thus, 
L-OHP suppressed tumor growth by just 14%, whereas CMG suppressed 
tumor growth by 49% and this difference was statistically significant 
(P < 0.05). The combination of L-OHP and CMG showed higher anti–tumor 
effects compared to monotherapy with each agent and significantly sup-
pressed tumor growth by 57% compared to the control group (P < 0.05).
3.5 | Safety profile is superior in curcumin β-D-
glucuronide group compared to L-OHP group
Compared to the control group, mean body weight was significantly 
lower on day 21 in L-OHP-treated mice (P < 0.01), but CMG or cur-
cumin did not show a negative impact on body weight (Figure 5A). 
White blood cell count, hemoglobin and platelet count of L-OHP-
administered groups significantly decreased compared to the con-
trol group (P < 0.01, Figure 5B). With regard to liver function, AST 
and ALT levels were elevated in the L-OHP monotherapy group 
compared to the control group, reflecting possible L-OHP-induced 
liver damage, while CMG significantly reduced AST and ALT levels 
compared to the control group (P < 0.01 and P < 0.05, respectively) 
(Figure 5C). Interestingly, AST/ALT elevation was reduced in the 
combination L-OHP and CMG group compared to the L-OHP mono-
therapy group, indicating that CMG has hepato-protective effects.
3.6 | High levels of free-form curcumin are 
maintained in tumor tissue
The levels of free-form curcumin in the serum, tumor tissue and major 
organs (heart, liver and spleen) on day 21 (after 48 hours following 
the final CMG administration on day 19) are shown in Figure 6. Free-
form curcumin levels were 15.2 ± 5.8 ng/mL and 136.9 ± 75.4 ng/g 
in the serum and tumor, respectively. In contrast, no free-form cur-
cumin was detected in the heart, liver and spleen.
3.7 | NF-κB activity is attenuated in curcumin β-D-
glucuronide-treated mice
We performed immunohistochemical analysis to test the NF-κB 
and IκB expression levels in the tumor samples extracted from the 
KRASm/TP53- HCT116 xenograft mice model on day 21 (Figure 7A-
D). A quantitative analysis showed that NF-κB staining signals were 
significantly lower in CMG-treated mice compared with control mice 
(P < 0.05, Figure 7E). Furthermore, IκB staining signals were higher in 
CMG-treated mice, although this difference did not reach statistical 
significance (Figure 7F). These data suggest that NF-κB activity in 
the tumor tissue was suppressed in the CMG-treated mice compared 
with the control mice.
4  | DISCUSSION
In this study, we demonstrated that KRAS activation and TP53 in-
activation could confer resistance to L-OHP in HCT116 cells. The 
IC50 of L-OHP for KRASm/TP53- HCT116 cells was more than five 
times higher than that of KRASw/TP53w cells (Figure 2A). NF-κB 
activity assessed by luciferase assay was significantly higher in 
KRASm/TP53- HCT116 cells compared to other two cell lines 
(Figure 3). Because both KRAS and TP53 mutations reportedly 
upregulate NF-κB activity and increase chemoresistance in other 
types of cancer,23-26 these results were in line with those of pre-
vious reports. Curcumin, which is known to be a potent NF-κB 
inhibitor,11,12 suppressed HCT116 cell growth irrespective of the 
F I G U R E  4   Efficacy of curcumin, curcumin β-D-glucuronide (CMG) and L-OHP on the KRASm/TP53w or KRASm/TP53- HCT116 
xenograft model. A, Tumor-bearing mice with KRASm/TP53w HCT116 cells were treated with curcumin, CMG, L-OHP, and the combination 
of CMG and L-OHP, as described in the Materials and Methods. Data represent means ± SD (n = 5-6). *P < 0.05, as compared to the control 
group on day 21. B, Tumor-bearing mice with KRASm/TP53- HCT116 cells were treated with CMG, L-OHP, and the combination of CMG and 
L-OHP, as described in the Materials and Methods. Data represent means ± SD (n = 7). *P < 0.05, as compared to the control group on day 
21, #P < 0.05, as compared to the L-OHP group on day 21
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KRAS/TP53 mutation profile in vitro. As expected, NF-κB activity 
was downregulated by curcumin in a dose-dependent manner in 
vitro. In line with our current observations, Porras et al reported 
that NF-κB activity is upregulated in acquired L-OHP-resistant 
CRC cells compared to parental cells and that treatment with cur-
cumin recovered the sensitivity to L-OHP.10 Therefore, we tested 
whether known NF-κB inhibitors could recover the efficacy of 
L-OHP on KRASm/TP53- HCT116 cells. As shown in supplemen-
tary Figure S2, all of the tested NF-κB inhibitors (Bay11-7082, 
TPCA1 and MG132) suppressed cell growth rates. Among them, 
MG132 recovered the efficacy of L-OHP to the same degree as 
that with curcumin. In contrast, Bay11-7082 and TPCA1 did not 
recover the efficacy of L-OHP. Unknown off-target effects of 
these two compounds might have affected complicated results.
Recently, we have succeeded in synthesizing CMG.21 CMG it-
self has no anticancer effects in vitro;27 however, we found that it is 
converted to a free-form curcumin by β-glucuronidase after intrave-
nous injection (Figure 1) and previously showed that it could achieve 
>1000 times higher plasma curcumin levels compared to those of 
orally administered curcumin.21 Herein, we aimed to clarify the ef-
ficacy, safety and pharmacokinetics of CMG using KRASm/TP53w 
and KRASm/TP53- HCT116 xenograft models. In the KRASm/
TP53w HCT116 xenograft model, CMG and L-OHP showed higher 
anti–tumor effects compared to orally administered curcumin, al-
though these differences did not reach statistical significance; 
however, the combination of L-OHP and CMG significantly sup-
pressed tumor growth compared to the control group (Figure 4A). 
F I G U R E  5   Body weight change, blood cell counts and AST/ALT levels on day 21 in KRASm/TP53w HCT116 xenograft model. A, Body 
weight change during curcumin, curcumin β-D-glucuronide (CMG) and L-OHP treatment. **P < 0.01, as compared to the control, curcumin 
and CMG group on day 21. B, Blood cell counts on day 21. *P < 0.01, as compared to the control and CMG groups. C, AST/ALT levels on day 
21 *P < 0.05, **P < 0.01, #P < 0.01 and ##P < 0.05, as compared to the control. ***P < 0.05, as compared to the L-OHP group
F I G U R E  6   Levels of free-form curcumin in the serum, tumor 
tissue and other major organs. Levels of free-form curcumin 
were measured after 48 hours following intraperitoneal CMG 
administration. Data represent means ± SD (n = 6-8). ND, not 
detected
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In contrast, the KRASm/TP53- HCT116 xenograft model showed 
a higher tumor growth rate than the KRASm/TP53w HCT116 xe-
nograft model, which was consistent with the in vitro data show-
ing that KRASm/TP53- cells have the highest IC50 of L-OHP and 
NF-κB activity. The mean tumor volume of the control group on day 
21 was 2.4 times larger than that of the KRASm/TP53w HCT116 
xenograft model. In the KRASm/TP53- HCT116 xenograft model, 
CMG showed significantly superior anti–tumor effects compared 
to L-OHP monotherapy (Figure 4B). In both the KRASm/TP53w 
and KRASm/TP53- HCT116 xenograft models, the combination 
of L-OHP with CMG groups showed additive anti–tumor effects 
without increasing toxicity. These results suggest that CMG mono-
therapy and combination of L-OHP with CMG could be promising 
treatments for L-OHP-resistant CRC. Supporting our hypothesis, 
Howells et al tested the efficacy of conventional curcumin in combi-
nation with FOLFOX in a randomized phase IIa trial for patients with 
advanced CRC and reported that combination of FOLFOX with 2 g 
daily oral curcumin improved overall survival compared to FOLFOX 
alone.28 However, because only 27 patients were enrolled and their 
baseline characteristics appeared to be different between two arms, 
these results need to be interpreted with caution and further stud-
ies are warranted.
With regard to safety, CMG did not cause any serious toxicity. 
In L-OHP-treated mice, significant body weight loss and severe my-
elosuppression, and AST/ALT elevation were observed, whereas 
none of these adverse events were observed in CMG-treated mice 
(Figure 5A-C). Liver damage, referred to as sinusoidal obstruction 
syndrome, is one of the major adverse events associated with 
L-OHP treatment and is observed in up to 50% of patients.29,30 
Interestingly, CMG reversed L-OHP-induced AST/ALT elevation, 
indicating that CMG has hepato-protective effects (Figure 5C). 
Further studies are warranted to clarify the underlying mechanisms.
β-glucuronidase, which is a key enzyme that hydrolyzes glu-
curonide prodrugs, such as CMG,31-33 could be attributable to 
the higher deposition of free-form curcumin in the tumor tissue 
(Figure 6). β-glucuronidase is secreted extracellularly in necrotic 
lesions by monocytes/granulocytes in tumor tissues, while it is 
localized to lysosomes in normal tissues.34 In line with our ob-
servation, Murdter et al tested the pharmacokinetics of glucuro-
nyl-spacer-doxorubicin prodrugs, which are converted to active 
doxorubicin by β-glucuronidase, and reported that deposition of 
doxorubicin in tumor tissue was increased when administering glu-
curonyl-spacer-doxorubicin prodrugs compared to standard doxo-
rubicin in xenograft models.35
F I G U R E  7   Immunohistochemical 
analysis of IκB and NF-κB. Serial sections 
of the tumors were immunostained for IκB 
or NF-κB (p65) antibodies. Representative 
images are shown (×400). A, IκB staining 
in control mice. B, NF-κB staining in 
control mice. C, IκB staining in CMG-
treated mice. D, NF-κB staining in CMG-
treated mice. E, A quantitative analysis 
of IκB staining signals. F, A quantitative 
analysis of NF-κB staining signals. Data 
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Our current study has the following limitation. We have demon-
strated that NF-κB activity was suppressed by free-form curcumin 
in vitro and by CMG in vivo; however, because free-form curcumin 
can affect a variety of molecules, we could not exclude the involve-
ment of mechanisms other than NF-κB inhibition in our experimen-
tal models. A recent study has clarified that curcumin perturbs 26S 
proteasome activity through direct inhibition of dual-specificity ty-
rosine phosphorylation-regulated kinase 2 (DYRK2), leading to tumor 
regression in the mice model.36 Because IκB degradation by prote-
asome is necessary for NF-κB activation, DYRK2-dependent pro-
teasome inhibition by free-form curcumin, which is converted from 
CMG in vivo, could lead to NF-κB inactivation. We have confirmed 
that curcumin suppresses proteasome activity in vitro and are now 
investigating whether DYRK2 is involved in the underlying mecha-
nisms in our models.
In summary, we have demonstrated that CMG could exert 
significant anti–tumor effects against the L-OHP-resistant CRC 
xenograft model with minimal toxicity. Pharmacokinetic analysis 
showed that CMG had a better distribution in the tumor tissue 
compared to that in blood or other major organs. Taken together, 
our data indicate that CMG could be a novel anticancer prodrug 
with a high safety profile, and we are continuing to develop this 
promising compound in combination with L-OHP for patients with 
CRC.
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